NEW YORK – Chinese single-cell technology firm Singleron Biotechnologies said on Monday that it has acquired Singapore-based Proteona.
Financial and other terms of the deal were not disclosed. Proteona offers single-cell biomarker discovery services to clinical and translational researchers. The deal provides Singleron with Proteona's network of customers and its technologies for single-cell multiomic analysis, including MapCell for cell annotation and MapBatch for batch correction.
"We are very excited about the opportunity to work with Proteona since both companies are focused on bringing breakthrough single-cell technologies to the clinic," Nan Fang, CEO and cofounder of Singleron, said in a statement. "Proteona's expertise in generating clinically relevant insights together with pharma partners and clinicians has enormous synergy with Singleron's vision to advance precision medicine by combining single-cell multiomics technologies and data science."
Founded in 2018, Singleron develops and commercializes single-cell multiomics products, including instruments, microfluidic devices, reagents, software analysis tools, and database solutions that facilitate high-throughput single-cell analysis. The firm also has offices in Cologne, Germany.